Overactive Bladder Treatment (OAB) Market Size to Hit USD 8.2 Bn by 2030

According to Nova one advisor, the global Overactive Bladder Treatment (OAB) market size is expected to hit around USD 8.2 billion by 2030 from valued at USD 3.9 billion in 2022 and growing at a CAGR of 4.6% from 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7056

Increasing number of patients with overactive bladder, adequate reimbursement policies for the treatment option available are some of the major factors upsurging the market growth. Additionally, increased investment in development of novel drugs and devices is furthermore expected to drive the growth of overactive bladder treatment market. However, product recalls and social stigma are some of the major reasons anticipated to restrict market growth.

Report Scope of the Overactive Bladder Treatment (OAB) Market

 Ask here for more customization study@  https://www.novaoneadvisor.com/report/customization/7056

Global Overactive Bladder Treatment Market Dynamics

DRIVER: Growing R&D investments and the launch of novel therapies in the coming years

At present, biopharmaceutical and pharmaceutical companies are investing in innovative therapies for overactive bladder treatment, which are expected to be launched during the forecast period. For instance, Taiho Pharmaceutical is developing TAC-302, a drug currently in Phase II development. This is an orally bioavailable drug that can be used to treat overactive bladder by stimulating neurite outgrowth activity in cultured peripheral neurons. The launch of novel treatment options will increase the adoption of treatment subsequently driving the growth of market.

RESTRAINT:  Frequent product recalls

Overactive bladder is a chronic medical condition that impacts the quality of life of a significant amount of the population. Frequent recalls of drugs used for treating OAB may limit market growth in the coming years. In June 2021, Cipla recalled 7,228 bottles of Solifenacin Succinate tablets in the US due to manufacturing issues. Such frequent recalls by leading pharmaceutical companies impede the growth of the overactive bladder treatment market.

OPPORTUNITY: Novel treatments, robust pipelines, and patent cliff of certain drugs

There are currently more than 30 candidates for OAB in clinical trial pipelines. Of these, three are in Phase II, seven in Phase III, and sixteen in Phase IV. This robust pipeline and the subsequent launch of newer drugs and therapies in the market are expected to drive the market for overactive bladder treatment. Samsung Medical Center is studying potential biomarkers such as Nerve Growth Factor (NGF), prostaglandin E2 (PGE2), and adenosine triphosphate (ATP) in OAB patients and the effect of these drugs on them. This will assist in predicting treatment responsiveness to provide individualized treatments. Such developments are expected to provide considerable growth opportunities for players in the OAB treatment market.

Mirabergon dominant the type segment in overactive bladder treatment market

Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing factors such as fewer side-effects & less risk of dementia. The neuromodulation segment is anticipated to grow at significant CAGR owing to increased adoption and investment by market players for launch of novel SNM & PTNS devices.

The idiopathic overactive bladder dominated the overactive bladder treatment market in 2021

Based on disease type, the overactive bladder treatment market is segmented into idiopathic and neurogenic overactive bladder syndromes. The idiopathic overactive bladder syndrome segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders. Furthermore, increased use of SNM therapy for the patients with idiopathic overactive bladder is anticipated to contribute towards the segmental growth.

North America accounted for largest share in overactive bladder treatment market in 2021

Geographically, the overactive bladder treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America held dominant share followed by Europe. The dominance of the region is attributable to the various factors such as increased incidence of patients with overactive bladder in US, favorable reimbursement policies for the treatment options. Additionally, preference of companies operating in the market coupled with ANDA and FDA approval for the various treatment is upsurging the growth of market in the region.

Recent Developments

• In March 2021, Myrbetriq  received the U.S. Food and Drug Administration approval to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.
• In December 2020, FDA approved GEMTESA (Vibegron) for the treatment of adults with overactive bladder (OAB). Vibegron is a small molecule, selective human beta-3 adrenergic agonist developed by Urovant Sciences, a subsidiary of Sumitovant Biopharma

Some of the prominent players in the Overactive Bladder Treatment (OAB) Market include:

 Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Medtronic Plc (Ireland), AbbVie Inc. (US), Viatris Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Johnson & Johnson Services, Inc. (US), Endo Pharmaceuticals Inc. (Ireland) and among others

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Overactive Bladder Treatment (OAB) market

By Type

• Anticholinergics
• Mirabegron
• BOTOX
• Neuromodulation
• Other Treatments.

By Disease Type

• Idiopathic Overactive Bladder
• Neurogenic Overactive Bladder

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7056

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/